Disease relevance of EVA1

• ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin's disease [1].
• PURPOSE: To evaluate the activity and toxicity of combined etoposide, vinblastine, and doxorubicin (EVA) in advanced Hodgkin's disease (HD) in relapse from or refractory to mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) [2].
• Combined effects of lipid peroxidation and antioxidant status on carotid atherosclerosis in a population aged 59-71 y: The EVA Study. Etude sur le Vieillisement Artériel [3].
• Differential association of common carotid intima-media thickness and carotid atherosclerotic plaques with parental history of premature death from coronary heart disease : the EVA study [4].
• Cognitive decline in individuals with high blood pressure: a longitudinal study in the elderly. EVA Study Group. Epidemiology of Vascular Aging [5].

Psychiatry related information on EVA1

• Risk of dementia in parents of probands with and without the apolipoprotein E4 allele. The EVA study [6].
• This paper reviews problems, associated with altitude decompression sickness; thermal regulation of the body, visual function and physiological psychological stress as well as individual EVA experience in physiological responses [7].

High impact information on EVA1

• This approach led us to the identification of a gene encoding a new member of the immunoglobulin superfamily, named epithelial V-like antigen (EVA), which is expressed in thymus epithelium and strongly downregulated by thymocyte developmental progression [8].
• EVA is highly homologous to the myelin protein zero and, in thymus-derived epithelial cell lines, is poorly soluble in nonionic detergents, strongly suggesting an association to the cytoskeleton [8].
• Its capacity to mediate cell adhesion through a homophilic interaction and its selective regulation by T cell maturation might imply the participation of EVA in the earliest phases of thymus organogenesis [8].
• Thirty-seven patients had received mechlorethamine, vinblastine, prednisolone, and procarbazine (MVPP) and 52 patients, a hybrid combination of chlorambucil, vinblastine, prednisolone, procarbazine, doxorubicin, vincristine, and etoposide (ChIVPP/EVA) [9].
• Longitudinal study of blood pressure and white matter hyperintensities: the EVA MRI Cohort [10].

Chemical compound and disease context of EVA1

• Primary systemic treatment of advanced Hodgkin's disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up [11].
• In EVA, the reduced GI toxicity of rofecoxib previously reported in other studies appeared to translate into a strong preference to continue this therapy in a large sample of patients [12].
• CONCLUSIONS: EVA offers a nonbleomycin-containing alternative for patients in whom preexisting pulmonary disease may be exacerbated by bleomycin and radiation therapy [13].

Biological context of EVA1

• Cross-sectional and 4-year longitudinal associations between brachial pulse pressure and common carotid intima-media thickness in a general population. The EVA study [14].
• Systemic oxidative stress and cognitive performance in the population-based EVA study. Etude du Vieillissement Artériel [15].
• Evaluation of a novel infrared range vibration-based descriptor (EVA) for QSAR studies. 1. General application [16].
• We show that EVA is expressed during the early stages of thymus organogenesis in both fetal thymic epithelia and T cell precursors, and is progressively downregulated from day 16.5 of embryonic development [17].
• Transgenic overexpression of EVA in the thymus cortex resulted in a modified stromal environment, which elicited an increase in organ size and absolute cell number [17].

Anatomical context of EVA1

• Relation of intima-media thickness to atherosclerotic plaques in carotid arteries. The Vascular Aging (EVA) Study [18].
• The purpose of this study was to regenerate the human periodontal ligament (PDL) around dental implants by using a hybrid structure of cells with materials, such as PDL cells + collagen + poly(ethylene-co-vinyl alcohol) (EVA) on titanium implant [19].
• Collectively, these data suggest a role for EVA in structural organisation of the thymus and early lymphocyte development [17].
• Morphologic study and syntheses of type I collagen and fibronectin of human periodontal ligament cells cultured on poly(ethylene-co-vinyl alcohol) (EVA) with collagen immobilization [19].
• Different types of polymeric membranes based on PVC (poly(vinyl chloride)) and EVA (ethyl-vinyl-acetate), without internal reference solution, were prepared using 5,10,15,20-tetraphenylporphyrinate (TPP) manganese(III) (Mn(III)TPP-Cl) as electroactive material [20].

Associations of EVA1 with chemical compounds

• The EVA regimen (etoposide 100 mg/m2 intravenously [IV] on days 1, 2, and 3; vinblastine 6 mg/m2 IV on day 1; and doxorubicin 50 mg/m2 IV on day 1) was administered every 28 days for a minimum of four and a maximum of six cycles [2].
• Effect of the angiotensin I-converting enzyme I/D polymorphism on cognitive decline. The EVA Study Group [21].
• Stability of reduced glutathione in solutions for organ preservation stored in multilayer bags versus EVA bags [22].
• RESULTS: The Tg of the bags fell into two groups: 70 to 105 degrees C (PO, FEP) and -50 to -17 degrees C (PVC with plasticizer, EVA) [23].
• Results from a patient survey to assess gastrointestinal burden of non-steroidal anti-inflammatory drug therapy contrasted with a review of data from EVA to determine satisfaction with rofecoxib [12].

Other interactions of EVA1

• Two genes were regulated in an opposite way: ID1 and EVA1 [24].

Analytical, diagnostic and therapeutic context of EVA1

• CONCLUSION: EVA is an effective second-line regimen for the treatment of HD in relapse following MOPP chemotherapy [2].
• After a median follow-up of 4.9 years, freedom from progression (FFP), event-free survival (EFS), and overall survival (OS) are all significantly better in the population treated with ChlVPP/EVA than VAPEC-B, where the comparative 5-year results are 82% and 62% (FFP), 78% and 58% (EFS), and 89% and 79% (OS), respectively [1].
• The potential interest of serum elastase activity (SEA) as a marker of vascular aging and atherosclerosis was studied as part of an epidemiological study on vascular and cognitive aging (EVA Study) [25].
• Those using EVA (ethyl-vinyl acetate; n = 28) orthoses presented results similar to those for the total group [26].
• Hormone replacement therapy use is associated with a lower occurrence of carotid atherosclerotic plaques but not with intima-media thickness progression among postmenopausal women. The vascular aging (EVA) study [27].

References